Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: p.G12C-mutated pancreatic cancer are unknown. METHODS: p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy. The primary objective of phase 1 was to assess safety and to identify the recommended dose for phase 2. In phase 2, patients received sotorasib at a dose of 960 mg orally once daily. The primary end point for phase 2 was a centrally confirmed objective response (defined as a complete or partial response). Efficacy end points were assessed in the pooled population from both phases and included objective response, duration of response, time to objective response, disease control (defined as an objective response or stable disease), progression-free survival, and overall survival. Safety was also assessed. RESULTS: The pooled population from phases 1 and 2 consisted of 38 patients, all of whom had metastatic disease at enrollment and had previously received chemotherapy. At baseline, patients had received a median of 2 lines (range, 1 to 8) of therapy previously. All 38 patients received sotorasib in the trial. A total of 8 patients had a centrally confirmed objective response (21%; 95% confidence interval [CI], 10 to 37). The median progression-free survival was 4.0 months (95% CI, 2.8 to 5.6), and the median overall survival was 6.9 months (95% CI, 5.0 to 9.1). Treatment-related adverse events of any grade were reported in 16 patients (42%); 6 patients (16%) had grade 3 adverse events. No treatment-related adverse events were fatal or led to treatment discontinuation. CONCLUSIONS: p.G12C-mutated advanced pancreatic cancer who had received previous treatment. (Funded by Amgen and others; CodeBreaK 100 ClinicalTrials.gov number, NCT03600883.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CodeBreaK100 (NCT03600883) clinical trial evaluated the safety and efficacy of sotorasib in advanced KRASG12C-mutant cancers, including 38 patients with metastatic, previously chemotherapy-treated PDAC. In these patients, a 21% objective response rate (ORR), a median progression-free survival (PFS) of 4.0 months, and a median overall survival (OS) of 6.9 months were observed (26).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [26]
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [16]
In the citing paper
“In the first published clinical series of KRASG12C inhibitor monotherapy in advanced PDAC, responses occurred in a minority of patients (~21%) and were generally transient75.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [75]
In the citing paper
“Even with recent advances in this space, currently only inhibitors targeting a specific KRAS mutation (KRAS G12C) have been FDA-approved in NSCLC (2–5).”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [5]
In the citing paper
“Although recently developed KRAS G12C inhibitors, 10 including sotorasib and adagrasib, have shown antitumor activity in patients with previously treated KRAS G12C-mutated cancer, the extent of the clinical benefit remains limited, and better therapies to target KRAS G12C remain a high priority.[11][12][13][14][15][16][17][18]”
From Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation (2023) · cites this paper as [15]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citation
Cited by
Items 101–200 of 579
Reißig, T. M., Tzianopoulos, I., Liffers, S.-T., Rosery, V., Guyot, M., Ting, S., Wiesweg, M., Kasper, S., Meister, P., Herold, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101539 · Cited by 17
Emerging Prognostic and Predictive Factors in Pancreatic Cancer
Karamitopoulou, E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100328 · Cited by 17
Witte, D. P., Pretzell, I., Reißig, T. M., Stein, A., Velthaus, J.-L., Alig, A. H. S., Bohnenberger, H., Knödler, M., Kurreck, A., Sulzer, S., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05954-5 · Cited by 18
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC
Tran, N. L., Jiang, J., Ma, M., Gadbois, G. E., Gulay, K. C. M., Verano, A. L., Schiavon, C. R., Rebollo, E., Zhou, H., Huang, C., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01978-1 · Cited by 17
Schmutz, M., Sommer, S., Sander, J., Graumann, D., Raffler, J., Soto‐Rey, I., Sheikhalishahi, S., Schmidt, L., Unkelbach, L. P., Ortak, L., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf293 · Cited by 21
Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma
Zheng, Y., Peng, H., Xu, H., Ou, Y., Wang, D., Wang, H., & Ren, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199395 · Cited by 16
Huffman, B. M., Feng, H., Parmar, K., Wang, J., Kapner, K. S., Kochupurakkal, B. S., Martignetti, D. B., Sadatrezaei, G., Abrams, T. A., Biller, L. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2005 · Cited by 17
Metastatic Pancreatic Cancer: Where Are We?
Hernández-Blanquisett, A., Quintero-Carreño, V., Martínez‐Ávila, M. C., Porto, M., Barbur, M. C. M., & Buendía, E. (2024) · Oncology Reviews · doi:10.3389/or.2023.11364 · Cited by 17
Toledo, B., Deiana, C., Scianò, F., Brandi, G., Marchal, J. A., Perán, M., & Giovannetti, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2319340 · Cited by 18
Ha, H., Lee, H. Y., Kim, J. H., Kim, D. Y., An, H. J., Bae, S., Park, H.-S., & Kang, J. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.128 · Cited by 17
Huerta, M., Martín-Arana, J., Gimeno-Valiente, F., Carbonell‐Asins, J. A., García-Micó, B., Martínez-Castedo, B., Robledo-Yagüe, F., Camblor, D. G., Fleitas, T., Bartolomé, M. G., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.05.003 · Cited by 16
HRS-4642: The next piece of the puzzle to keep KRAS in check
Flores-Gómez, A. A., & Drosten, M. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.005 · Cited by 17
Peng, L., Liang, Y., Guo, X., Zhang, Q. W., Gao, Z., Kong, X., Zhang, H., Zhu, B., & Cui, D. (2025) · Nanoscale Advances · doi:10.1039/d5na00513b · Cited by 16
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 15
Cui, J., Jiang, K., Li, W., Ni, S., Zong, H., Du, J., He, Y., Liu, Z., Kong, G., Zhang, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04538-9 · Cited by 16
Herzberg, B. O., & Manji, G. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad014 · Cited by 16
RAS Pathway Mutations and Therapeutics in Vascular Anomalies
Alharbi, S., Merkle, S., Hammill, A. M., Waters, A. M., & Cras, T. D. L. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31605 · Cited by 15
Jazieh, K., Tsai, J., Solomon, S. R., Zhu, M., Sinicrope, F. A., Pedersen, K. S., Fernández-Zapico, M. E., & Xie, H. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2948 · Cited by 15
Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic
Wang, Y., Xu, G., & Xia, H. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf178 · Cited by 15
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions
Peng, C., & Oberstein, P. E. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01352-2 · Cited by 14
Cheng, C., Hou, K., Hsu, C., & Chiang, L. (2023) · Advanced Science · doi:10.1002/advs.202304926 · Cited by 14
Jabbour, S. K., Kumar, R. N., Anderson, B. M., Chino, J., Jethwa, K. R., McDowell, L. J., Lo, A., Owen, D., Pollom, E. L., Tree, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.010 · Cited by 14
Hajjo, R., Sabbah, D. A., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327307 · Cited by 16
Advancements in Preclinical Models of Pancreatic Cancer
Salu, P., & Reindl, K. M. (2024) · Pancreas · doi:10.1097/mpa.0000000000002277 · Cited by 15
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Reshkin, S. J., Cardone, R. A., & Koltai, T. (2024) · Cells · doi:10.3390/cells13070602 · Cited by 14
Keane, F., Chou, J. F., Walch, H. S., Schoenfeld, J. D., Singhal, A., Cowzer, D., Harrold, E. C., O'Connor, C. A., Park, W., Varghese, A. M., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae095 · Cited by 13
Self-citationGenomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
Aparicio, T., Henriques, J., Svrcek, M., Zaanan, A., Manfrédi, S., Gardini, A. C., Tougeron, D., Gornet, J., Jary, M., Terrebonne, É., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02687-7 · Cited by 13
Trends in the treatment of advanced pancreatic cancer
Momose, H., Kudo, S., Yoshida, T., Hasui, N., Matsuki, R., Kogure, M., & Sakamoto, Y. (2024) · BioScience Trends · doi:10.5582/bst.2024.01156 · Cited by 13
Zhang, T., Zhou, Y., Wu, Y. H., Shi, M., Sun, W., & Wang, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-97233-7 · Cited by 14
Shenoy, A., Yousif, A., & Hussain, M. D. (2025) · Cancers · doi:10.3390/cancers17081319 · Cited by 14
Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review
Zaitouni, S. E., Laraqui, A., Boustany, Y., Benmokhtar, S., Annaz, H. E., Abi, R., Tagajdid, M. R., Kochri, S. E., Bouaiti, E. A., Amine, I. L., et al. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251331759 · Cited by 13
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma
Sarfraz, H. R., Saha, A., Jhaveri, K. S., & Kim, D. W. (2023) · Current Oncology · doi:10.3390/curroncol30060404 · Cited by 13
Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
Kumar, P. A., Serinelli, S., Zaccarini, D. J., Huang, R. S. P., Danziger, N. A., Janovitz, T., Basnet, A., Sivapiragasam, A., Graziano, S. L., & Ross, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1169586 · Cited by 13
Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer
Safyan, R. A., Kim, E., Dekker, E. N., Homs, M. Y. V., Aguirre, A. J., Koerkamp, B. G., & Chiorean, E. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438598 · Cited by 12
KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
Gelfer, R., Gulla, A., Kalvin, H. L., Song, Y., Harding, J. J., Abou‐Alfa, G. K., O'Reilly, E. M., Park, W., Chandwani, R., Wei, A. C.-C., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00263 · Cited by 13
Ramalingam, P. S., Chellasamy, G., Hussain, M. S., Muthukaliannan, G. K., Hussain, T., Alrokayan, S., Yun, K., Ramaiah, M. J., & Arumugam, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1635449 · Cited by 14
Drosten, M., & Barbacid, M. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70149 · Cited by 12
McAndrews, K. M., Mahadevan, K. K., Li, B., Comptdaer, A. M., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00854-5 · Cited by 12
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
Su, Y., Chiang, N., Chiu, T., Huang, C., Hsu, S., Lin, H., Yang, S., Yang, Y., Chou, W., Chen, Y., et al. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100696 · Cited by 13
Multidisciplinary Therapeutic Approaches to Pancreatic Cancer According to the Resectability Status
Mauro, A., Faverio, C., Brizzi, L., Mazza, S., Scalvini, D., Alfieri, D., Cappellini, A., Chicco, F., Ciccioli, C., Delogu, C., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041167 · Cited by 12
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma
Keane, F., Saadat, L. V., O'Connor, C. A., Chou, J. F., Bowman, A. S., Xu, F., Crowley, F., Debnath, N., Schoenfeld, J. D., Singhal, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf139 · Cited by 11
Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer
Bryant, J. M., Ruffolo, L. I., Soares, K. C., Hoffe, S. E., & Lowy, A. M. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191944 · Cited by 12
Lyubetskaya, A., Rabe, B. A., Kavran, A. J., Bai, Y., Fisher, A., Font‐Tello, A., Lewin, A. C., Pliner, H. A., Fan, Y., Giampapa, L., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116827 · Cited by 11
Hafner, P., Keller, S. J., Chen, X., Alrawashdeh, A. Y., Jumaa, H., Nollmann, F. I., Besson, S., Kemming, J., Gorka, O., Das, T., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02563-7 · Cited by 12
RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming
Miller‐Phillips, L., & Collisson, E. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01096-x · Cited by 11
Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience
Ohtsu, A., Goto, K., & Yoshino, T. (2023) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.99.015 · Cited by 11
Luo, W. P., Zhu, J., Zhang, W., Yu, A., Zhou, W., & Xu, K. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2282606 · Cited by 12
Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Bhamidipati, D., Yedururi, S., Huse, J. T., Chinapuvvula, S. V., Wu, J., & Subbiah, V. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00252 · Cited by 11
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors
Kareff, S. A., Trabolsi, A., Krause, H. B., Samec, T., Elliott, A., Rodríguez, E., Olazagasti, C., Watson, D. C., Bustos, M. A., Hoon, D. S. �., et al. (2024) · Cancers · doi:10.3390/cancers16081572 · Cited by 12
Imperial, R. J. L., Mosalem, O. M., Majeed, U., Tran, N. H., Borad, M. J., & Babiker, H. M. (2024) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s390655 · Cited by 10
Emerging Tumor-Agnostic Molecular Targets
Bhamidipati, D., & Schram, A. M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0725 · Cited by 11
Kim, M. K., Cho, I. R., Kim, Y., Choi, J. H., Jung, K., Kim, J., Kim, S., Yun, H., Yoon, J., Oh, D. Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241290482 · Cited by 10
Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First
Reiss, K. A., Soares, K. C., Torphy, R. J., & Gyawali, B. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473204 · Cited by 10
Hibshman, P. S., Stalnecker, C. A., Klomp, J. A., Drizyte‐Miller, K., Klomp, J. E., Edwards, A. C., Pita, L. M., Hodge, R. G., Diehl, J. N., Mouery, R. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adu7145 · Cited by 10
Vascular malformations: from genetics to therapeutics
Morin, G., Galasso, I., & Canaud, G. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00344-x · Cited by 10
Bhamidipati, D., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101591 · Cited by 10
Mahmood, U., Carrier, E., & Khan, K. H. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102750 · Cited by 11
Prognostic impact of caspase‐8 mutation in oral cavity squamous cell carcinoma
Lu, H., Su, C., Su, S., Chang, L., Wu, M., Lin, C., & Yang, S. (2024) · Oral Diseases · doi:10.1111/odi.15124 · Cited by 10
Redefining pancreatic cancer management with tumor-agnostic precision medicine
Reddy, N. K., & Subbiah, V. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae066 · Cited by 11
Luan, X., Wang, X., Bian, G., Li, X., Gao, Z., Liu, Z., Zhang, Z., Han, T., Zhao, J., Zhao, H., et al. (2024) · Oncology Reports · doi:10.3892/or.2024.8846 · Cited by 13
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Tian, L., Liu, C., Zheng, S., Shi, H., Fang, W., Jiang, W., Dong, Y., Xu, H., Yin, E., Sun, N., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06089-y · Cited by 11
Pancreatic cancer subtyping - the keystone of precision treatment
Fan, Z., Xiao, Y., Du, Y., Zhang, Y., & Zhou, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563725 · Cited by 14
Hu, Q., Feng, J., Qi, L., & Jin, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c10404 · Cited by 9
Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients
Riner, A. N., Velazquez-Villarreal, E. I., Rajpara, S., Qian, J., Jin, Y., Loza, D., Akki, A. S., Herremans, K. M., Raj, R., Williams, T. M., et al. (2025) · Pancreas · doi:10.1097/mpa.0000000000002408 · Cited by 9
Self-citationImmune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting
Liang, K.-L., & Azad, N. S. (2025) · Cancers · doi:10.3390/cancers17071246 · Cited by 10
Toyokuni, E., Horinaka, M., Nishimoto, E., Yoshimura, A., Fukui, M., & Sakai, T. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0831 · Cited by 10
Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D
Budai, B., Vaupel, A., Dickson, C. J., Beyer, K. S., Guthy, D. A., Ostermann, N., McGregor, L. M., de Kanter, R., Weiss, A., Linder, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01214 · Cited by 9
Barrambana, S., Zamorano-Domínguez, E., Liaki, V., & Guerra, C. E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115652 · Cited by 10
Integrative genomic identification of therapeutic targets for pancreatic cancer
Guo, J. A., Gong, D. H., Evans, K. E., Takahashi, K., Jambhale, A. D., Shiau, C., Yu, P. Z., Wang, S., Wu, W., Chugh, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116191 · Cited by 9
Actionable mutations in pancreatic cancer: where targeted therapies are making a difference
Fivaz, M., Bornand, A., Corrò, C., Koessler, T., & Genoud, V. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2025-001925 · Cited by 9
KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020873 · Cited by 9
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 10
KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
Osta, B. E. E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-174 · Cited by 10
Pancreatic cancer in young adults - an evolving entity?
Li, Y., & Zhang, X. (2023) · PubMed Central · Cited by 14
Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer
Xing, F., Qin, Y., Xu, J., Wang, W., & Zhang, B. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00875-z · Cited by 9
Skorupan, N., Peer, C. J., Zhang, X., Choo‐Wosoba, H., Ahmad, M. I., Lee, M.-J., Rastogi, S., Sato, N., Yu, Y., Pegna, G. J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1386190 · Cited by 9
Recent advances in the treatment of pancreatic cancer
Ma, Y., Zhang, F., & Yang, Y. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00089-6 · Cited by 9
Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
Dang, S., Zhang, S., Zhao, J., & Li, W. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03449-8 · Cited by 9
López-Estévez, A. M., Sanjurjo, L., Turrero, Á., Arriaga, I., Abrescia, N. G. A., Poveda, A. M., Jiménez‐Barbero, J., Vidal, A., Torres, D., & Alonso, M. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.032 · Cited by 9
Nicolle, R., Canivet, C., Palazzo, L., Napoléon, B., Ayadi, M., Pignolet, C., Cros, J. F., Gourgou, S., Sèlves, J., Torrisani, J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105373 · Cited by 12
Tinsley, S. L., Chianis, E. R. D., Shelley, R. A., Mall, G. K., Dhiman, A., Baral, G., Kothandaraman, H., Thoma, M. C., English, I. A., Daniel, C. J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03196-w · Cited by 11
Jameson, N. M., Kim, D., Lee, C., Skrable, B., Shea, A., Guo, X., Izadi, H., Abed, M., Harismendy, O., Ma, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0411 · Cited by 9
Su, D., Ruan, Y., Shi, Y., Cao, D., Wu, T., Dang, T., Wang, H., Xin, Y., Ma, M., Meng, H., et al. (2025) · Cancer Science · doi:10.1111/cas.16456 · Cited by 9
Huo, Q., Li, K., Sun, X., Zhuang, A., Minami, K., Tamari, K., Ogawa, K., Fishel, M. L., Li, B., & Yokota, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-41835-6 · Cited by 9
Ruff, S. M., & Pawlik, T. M. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2903101 · Cited by 9
Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Aref, A. T., Grealey, J., Pathan, M., Noor, Z., Anees, A., Azad, A., Smith, D. L., Humphries, E. M., Bucio-Noble, D., Koh, J. M. S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0229 · Cited by 8
Reichinger, A., Friedrich, A. W., Lentner, T., Taghizadeh, H., Reimann, P., Nothdurfter, D., Burghofer, J., Windhager, H., Kirchweger, P., Webersinke, G., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105827 · Cited by 8
Emerging therapeutic advancements in pancreatic cancer: a contemporary review
Malla, M., Sakr, Y., Gupta, G., Akce, M., & El‐Rayes, B. F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03027-8 · Cited by 8
Cho, D., Shin, K., Hong, T. H., Lee, S. H., Kim, Y.-H., Kim, I.-H., Hong, S. H., Lee, M. A., & Park, S. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210908 · Cited by 8
Principe, D. R., Becker, J. H., Metropulos, A. E., Marinelarena, A. M., Pham, T. D., Aissa, A. F., & Munshi, H. G. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0483 · Cited by 10
Xu, X., Chen, X., Xu, R., Huo, Z., Li, C., Nowsheen, S., Aziz, K., Yao, F., Lou, Z., & Deng, M. (2026) · Nature Communications · doi:10.1038/s41467-026-69695-4 · Cited by 9
Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions
Nagaraju, G. P., Nellipudi, H. R., Ganji, C., Kuppala, V., Ganji, S. P., Kumari, S., Farran, B., Srilatha, M., Guenter, R. E., & El‐Rayes, B. F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02705-5 · Cited by 9
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel, D., Kim, J., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s403614 · Cited by 8
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
Jeong, S. Y., Hong, J. Y., Park, J. O., Park, Y. S., Lim, H. Y., Jang, J. Y., Jeon, Y., & Kim, S. T. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231170484 · Cited by 9
Top advances of the year: Pancreatic cancer
Warren, E. A. K., Lesinski, G. B., & Maithel, S. K. (2023) · Cancer · doi:10.1002/cncr.35031 · Cited by 8
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1043 · Cited by 8
Codon-specific KRAS mutations predict survival in advanced pancreatic cancer
Boilève, A., Rousseau, A., Hilmi, M., Tarabay, A., Mathieu, J. R. R., Cartry, J., Bedja, S., Goudarzi, N., Nicotra, C., Ngo‐Camus, M., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100030 · Cited by 9
Self-citationChristenson, E. S., Yu, R. Y.-L., Gai, J., Wang, H., Lei, M., & Zheng, L. (2024) · Annals of Pancreatic Cancer · doi:10.21037/apc-24-2 · Cited by 8
Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era
Nicoletti, A., Paratore, M., Vitale, F., Negri, M., Quero, G., Esposto, G., Mignini, I., Alfieri, S., Gasbarrini, A., Zocco, M. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147623 · Cited by 8
Yousef, M., Hurd, M. W., Yousef, A. M. G., Ludmir, E. B., Pillai, A. B., Peterson, J., Koay, E. J., Albarouki, S., Tzeng, C.-W. D., Snyder, R. A., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae182 · Cited by 8
Metadata
- Authors
- Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., Vincent, M., Sunakawa, Y., Dahan, L., Bajor, D., Rha, S.-Y., Lemech, C., Juric, D., Rehn, M., Ngarmchamnanrith, G., Jafarinasabian, P., Tran, Q., & Hong, D. S.
- Affiliations
- Kansai Medical University (JP)
- From Duke University Medical Center, Durham, NC (J.H.S.); Kansai Medical University, Shinmachi, Hirakata (H.S.), and St. Marianna University School of Medicine, Kawasaki (Y.S.) — both in Japan; University of Florida, Gainesville (T.J.G.); Memorial Sloan Kettering Cancer Center, New York (R.Y.); Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif (A.H.), and Marseille University Hospital, Marseille (L.D.) — both in France; Huntsman Cancer Institute, University of Utah, Salt Lake City (I.G.-L.); West German Cancer Center, University Hospital Essen, Essen (M.S.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (T.F.B.); Fred Hutchinson Cancer Center, University of Washington, Seattle (A.L.C.); Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); London Regional Cancer Program, London, ON, Canada (M.V.); University Hospitals Cleveland Medical Center, Cleveland (D.B.); Yonsei Cancer Center, Seoul, South Korea (S.-Y.R.); Scientia Clinical Research and Prince of Wa...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-05
- Volume
- 388
- Issue
- 1
- Pages
- 33-43
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10506456
- OpenAlex
- W4312094134
- Semantic Scholar
- 488922b069e36918a499827187276c02b891cb58
- Cited by
- 527
- References
- 34
- Citations by year
- 2026: 138 · 2025: 169 · 2024: 142 · 2023: 78
- FWCI
- 40.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Amgen Inc.
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- sotorasib, KRAS G12C mutation, advanced pancreatic cancer, KRAS inhibitors, metastatic pancreatic cancer, previously treated patients, objective response, progression-free survival, overall survival, treatment safety, adverse events
- MeSH terms
- Immune Checkpoint Inhibitors, Administration, Oral, Humans, Lung Neoplasms, Mutation, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.